Adding bedaquiline or delamanid to background regimen for treatment of multi-drug resistant tuberculosis: a cost-effectiveness analysis

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: YOU, Joyce (The Chinese University of Hong Kong, School of Pharmacy, Shatin, Hong Kong SAR China)
  • Co-author(s): Wai-Ying Yip School of Pharmacy, The Chinese University of Hong Kong, Shatin, Hong Kong
    Joyce You
  • Abstract:

    Background

    Multi-drug resistant tuberculosis (MDR-TB) is a growing global threat, especially in the Asia region. Background regimens (BRs) for MDR-TB treatment are usually poorly tolerated with moderate success rate. Two anti-TB agents (bedaquiline and delamanid) with improved sputum conversion rates in clinical trials are recently licensed for..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login